NCT03624010 Phase 2 Completed
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients Study sponsor: Tenax Therapeutics, Inc. · TENX
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2023-04-25 Actual
Enrollment · participants 35 Actual
Source updated 2026-04-22 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-02-19 · 3 fields changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: Clinical Safety measured by number of adverse events (AEs )
+ Updated value measure: Clinical Safety
The saved outcome text may be shortened. Check the source for full wording.
Enrollment · participant count Recorded edit − Previous value count: 20; type: ACTUAL
+ Updated value count: 35; type: ACTUAL
Primary completion date Recorded edit − Previous value 2024-02-01
+ Updated value 2023-04-25
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial